{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:19:05Z","timestamp":1790176745170,"version":"4.1.0"},"reference-count":162,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2015,4,3]]},"DOI":"10.1517\/14712598.2015.993375","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T05:57:54Z","timestamp":1418277474000},"page":"529-546","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":71,"title":["Glycoconjugate vaccines: an update"],"prefix":"10.1517","volume":"15","author":[{"given":"Mairi","family":"Vella","sequence":"first","affiliation":[{"name":"Mater Dei Hospital, Department of Paediatrics","place":["Malta"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pace","sequence":"additional","affiliation":[{"name":"Consultant Infectious Disease Paediatrician, Postgraduate Training Coordinator in Child and Adolescent Health Mater Dei Hospital, Department of Paediatrics,","place":["Malta"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,12,11]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61203-4"},{"key":"e_1_3_2_4_1","unstructured":"World Health Organization. Global Immunization Data. 2014. Available from: http:\/\/www.who.int\/immunization\/monitoring_surveillance\/Global_Immunization_Data.pdf [Accessed 20 August 2014]"},{"key":"e_1_3_2_5_1","unstructured":"World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age. 2008. Available from: http:\/\/www.who.int\/immunization\/monitoring_surveillance\/burden\/estimates\/Pneumo_hib\/en\/ [Accessed 2 September 2014]"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-346-2_1"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.063"},{"key":"e_1_3_2_8_1","unstructured":"World Health Organization. Meningococcal disease in countries of the African meningitis belt 2012 \u2013 emerging needs and future perspectives. 2013. Available from: http:\/\/www.who.int\/wer\/2013\/wer8812.pdf [Accessed 21 August 2014]"},{"key":"e_1_3_2_9_1","unstructured":"Centers for Disease Control and Prevention. Meningococcal Disease: Technical & Clinical Information. 2014. Available from: http:\/\/www.cdc.gov\/meningococcal\/clinical-info.html [Accessed 4 September 2014]"},{"key":"e_1_3_2_10_1","unstructured":"Centers for Disease Control and Prevention. Pneumococcal Disease. 2013. Available from: http:\/\/www.cdc.gov\/pneumococcal\/clinicians\/clinical-features.html [Accessed 17 July 2014]"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.088"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.2.13717"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2006.00051.x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/520303"},{"key":"e_1_3_2_15_1","first-page":"2049","article-title":"Prevention of meningococcal disease","volume":"72","author":"Kimmel SR","year":"2005","unstructured":"Kimmel SR. Prevention of meningococcal disease. Am Fam Physician 2005;72:2049-56","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.725718"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"Daugla DM Gami JP Gamougam K et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study Lancet. 2014;383:40-7","DOI":"10.1016\/S0140-6736(13)61612-8"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7542800"},{"key":"e_1_3_2_19_1","volume-title":"Sherris medical microbiology","author":"Ryan KJ","year":"2004","unstructured":"Ryan KJ, Ray CG. Sherris medical microbiology. USA; McGraw Hill; 2004"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.074"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1542\/peds.85.4.643","article-title":"Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine","volume":"85","author":"Shapiro ED","year":"1990","unstructured":"Shapiro ED, Berg AT. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine. Pediatrics 1990;85:643-7","journal-title":"Pediatrics"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit579"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2010.25.1.90"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500020055031"},{"key":"e_1_3_2_25_1","unstructured":"Centers for Disease Control and Prevention. Prevention and Control of Haemophilus influenzae Type b Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). 2014. Available from: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6301a1.htm [Accessed 4 September 2014]"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268813000083"},{"key":"e_1_3_2_27_1","unstructured":"Public Health England. Haemophilus influenzae Epidemiological Data. Available from: http:\/\/webarchive.nationalarchives.gov.uk\/20140714084352\/http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/HaemophilusInfluenzaeTypeB\/EpidemiologicalData\/ [Accessed 4 September 2014]"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05476-11"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.77.6.488"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/600292"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.11.027"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13171-6"},{"issue":"3","key":"e_1_3_2_33_1","first-page":"58","article-title":"Invasive Haemophilus influenzae Type B disease in five young children\u2013Minnesota, 2008","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","unstructured":"Centers for Disease Control and Prevention. Invasive Haemophilus influenzae Type B disease in five young children\u2013Minnesota, 2008. MMWR Morb Mortal Wkly Rep 2009;58(3):58-60","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7467.655"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.4049\/jimmunol.128.3.1267","article-title":"Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B","volume":"128","author":"Insel RA","year":"1982","unstructured":"Insel RA, Anderson PW. Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B. J Immunol 1982;128:1267-70","journal-title":"J Immunol"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05675-11"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.03.075"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00028-13"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1603.090290"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1906.121805"},{"key":"e_1_3_2_41_1","unstructured":"GAVI Alliance. Hib Initiative: a GAVI success story. 2011. Available from: http:\/\/www.gavi.org\/library\/news\/roi\/2010\/hib-initiative\u2013a-gavi-success-story\/ [Accessed 3 July 2014]"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.03.031"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1095209"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00144-06"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31824a9c37"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181ccb0a0"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.03.032"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66788-8"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.03.023"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.10.13017"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.020016-0"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.078"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199915001-00001"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.017"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1086\/648593"},{"key":"e_1_3_2_56_1","unstructured":"Kaye P Malkani R Martin S et al. Invasive Pneumococcal Disease (IPD) in England and Wales after 7 -valent conjugate vaccine (PCV7); Potential impact of 10 and 13 valent vaccines. Presented at the 27th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). 9 \u2013 13 June 2009; Brussels Belgium"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-008-0031-x"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.84"},{"key":"e_1_3_2_59_1","unstructured":"European Medicines Agency. Synflorix pneumococcal polysaccharide conjugate vaccine (adsorbed). 2014. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000973\/human_med_001071.jsp&mid=WC0b01ac058001d124 [Accessed 16 June 2014]"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70224-4"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074906"},{"key":"e_1_3_2_62_1","first-page":"1238","article-title":"Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae","volume":"12","author":"Bieging KT","year":"2005","unstructured":"Bieging KT, Rajam G, Holder P, et al. Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae. Clin Diagn Lab Immunol 2005;12:1238-42","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318199f8ef"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-10-4"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001657"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61854-6"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68304-9"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.113"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.10.16794"},{"key":"e_1_3_2_70_1","unstructured":"Wyeth Pharmaceutical. PREVNAR 13 Product specifications booklet. 2014. Available from: http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=501 [Accessed 3 September 2014]"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3027"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00062-10"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-1405"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.008"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1139\/cjm-2013-0614"},{"key":"e_1_3_2_76_1","unstructured":"Public Health England. Numbers of laboratory confirmed invasive pneumococcal disease cases by age group in England and Wales 1996-2005. 2008. Available from: http:\/\/webarchive.nationalarchives.gov.uk\/20140714084352\/http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/Pneumococcal\/EpidemiologicalDataPneumococcal\/BackgroundEpidemiologyPneumococcal\/IPDGraphs\/pneumoNumberLabConfirmedAgeSpecific\/ [Accessed 13 August 2014]"},{"issue":"112","key":"e_1_3_2_77_1","first-page":"5","article-title":"13-valent pneumococcal conjugate vaccine","volume":"20","year":"2011","unstructured":"13-valent pneumococcal conjugate vaccine. Prescrire Int 2011;20(112):5-7; 9","journal-title":"Prescrire Int"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.025"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.008"},{"key":"e_1_3_2_80_1","first-page":"89","article-title":"Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13 - valent polysaccharide conjugate vaccine","volume":"105","author":"Alicino C","year":"2014","unstructured":"Alicino C, Barberis I, Orsi A, Durando P. Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13 - valent polysaccharide conjugate vaccine. Minerva Med 2014;105:89-97","journal-title":"Minerva Med"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.085"},{"key":"e_1_3_2_82_1","unstructured":"FDA. PREVNAR 13 VRBPAC Adult Indication Briefing Document. 2011. Available from: http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/bloodvaccinesandotherbiologics\/vaccinesandrelatedbiologicalproductsadvisorycommittee\/ucm279680.pdf [Accessed 5 September 2014]"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1729"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1086\/600045"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.824419"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000056"},{"key":"e_1_3_2_87_1","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Nuorti JP","year":"2010","unstructured":"Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59:1-18","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.02.017"},{"key":"e_1_3_2_89_1","unstructured":"Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine Preventable Diseases. 2012. Available from: http:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/front-portion.pdf [Accessed 28 August 2014]"},{"key":"e_1_3_2_90_1","unstructured":"Bryant K Frenck R Gurtman A et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18\u201349 years na\u00efve to 23-valent pneumococcal polysaccharide vaccine. Presented at the 23rd ECCMID (European Society of Clinical Microbiology and Infectious Diseases). 27 \u2013 30th April 2013; Berlin"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2009.05.010"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-70"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-101"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-11-21"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.145"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2011.47.3.1556471"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.04.069"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03866.x"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.03.066"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000348"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.4314\/pamj.v8i1.71081"},{"key":"e_1_3_2_102_1","unstructured":"UNICEF\/WHO. Expanding immunization coverage. 2011. Available from: http:\/\/www.unicef.org\/immunization\/index_coverage.html [Accessed 4 September 2014]"},{"key":"e_1_3_2_103_1","unstructured":"GAVI Alliance. Advance Market Commitment for Pneumococcal Vaccines 2014. Available from: http:\/\/www.gavi.org\/search\/?SearchText=%20Pneumococcal%20AMC%20annual%20report [Accessed 9 September]"},{"key":"e_1_3_2_104_1","unstructured":"HealthyPeople.gov. Immunization and Infectious Diseases. 2014. Available from: http:\/\/www.healthypeople.gov\/2020\/topicsobjectives2020\/overview.aspx?topicid=23 [Accessed 3 July 2014]"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314476110"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.083"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22302"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.21794"},{"key":"e_1_3_2_109_1","unstructured":"Novartis Vaccines and Diagnostics S.r.l. MENVEO Product specifications booklet. Available from: http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm201349.pdf [Accessed 1 September 2014]"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00299-7"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03594-7"},{"key":"e_1_3_2_112_1","unstructured":"Public Health England. Meningococcal disease: laboratory confirmed cases in England and Wales. 2014. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/343375\/Table_1a_Invasive_meningococcal__E_W_by_capsular_group___epi_year.pdf [Accessed 20 August 2014]"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16725-1"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.03.045"},{"key":"e_1_3_2_115_1","first-page":"E060302.4","article-title":"Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules","volume":"11","author":"Cameron C","year":"2006","unstructured":"Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill 2006;11:E060302.4","journal-title":"Euro Surveill"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00529-09"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31824f34e6"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1086\/508776"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200208000-00010"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39563.545255.AE"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1086\/652765"},{"key":"e_1_3_2_122_1","unstructured":"Public Health England. Meningococcal C Conjugate Vaccine \u2013 Information about the \u2018freshers\u2019 dose. 2014. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/298443\/MenC_vaccine_for_new_uni_students_March2014.pdf [Accessed 3 September 2014]"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-303893"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100651"},{"key":"e_1_3_2_125_1","unstructured":"Centers for Disease Control and Prevention. Infant Meningococcal Vaccination: advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale. 2013. Available from: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6203a3.htm [Accessed 4 September 2014]"},{"key":"e_1_3_2_126_1","unstructured":"Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). 2013. Available from: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6202a1.htm [Accessed 2 September 2014]"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-2380"},{"key":"e_1_3_2_128_1","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report Emerging Infections Program Network Neisseria meningitidis 2012. Available from: http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mening12.html [Accessed 18 August 2014]"},{"key":"e_1_3_2_129_1","first-page":"R49","article-title":"Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales","volume":"7","author":"Ramsay M","year":"1997","unstructured":"Ramsay M, Kaczmarski E, Rush M, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997;7:R49-54","journal-title":"Commun Dis Rep CDR Rev"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1086\/527401"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1086\/649209"},{"key":"e_1_3_2_132_1","unstructured":"GlaxoSmithKline Biologicals. MenHibrix Product specifications booklet. Available from: http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm308577.pdf [Accessed 8 June 2014]"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-2992"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181c3ce88"},{"key":"e_1_3_2_135_1","unstructured":"Nimenrix. Summary of product characteristics. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/26514 [Accessed 17 November 2014]"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.009"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-116"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-012-1924-0"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.10.001"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S36243"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis892"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-363"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003812"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.038"},{"key":"e_1_3_2_145_1","doi-asserted-by":"crossref","unstructured":"Savage N. Logistics: Keeping cool: Nature international weekly journal of science. 2014. Available from: http:\/\/www.nature.com\/nature\/journal\/v507\/n7490_supp\/full\/507S8a.html [Accessed 2 September 2014]","DOI":"10.1038\/507S8a"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-576"},{"key":"e_1_3_2_147_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid0705.010513"},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.10.5129-5135.2005"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019513"},{"key":"e_1_3_2_150_1","doi-asserted-by":"crossref","unstructured":"Glassman M Duran D Sumner A. Global Health and the New Bottom Billion: How Funders Should Respond to Shifts in Global Poverty and Disease Burden. 2012. Available from: http:\/\/www.cgdev.org\/doc\/full_text\/BottomBillion\/Glassman_Bottom_Billion.html [Accessed 2 September 2014]","DOI":"10.2139\/ssrn.1972332"},{"key":"e_1_3_2_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62424-1"},{"key":"e_1_3_2_152_1","unstructured":"UNICEF. Ukraine Statistics. 2013. Available from: http:\/\/www.unicef.org\/infobycountry\/ukraine_statistics.html [Accessed 30 August 2014]"},{"key":"e_1_3_2_153_1","unstructured":"UNICEF. Egypt Statistics. 2013. Available from: http:\/\/www.unicef.org\/infobycountry\/egypt_statistics.html [Accessed 4 September 2014]"},{"key":"e_1_3_2_154_1","unstructured":"UNICEF. Syria Statistics. 2013. Available from: http:\/\/www.unicef.org\/infobycountry\/syria_statistics.html [Accessed 4 September 2014]"},{"key":"e_1_3_2_155_1","unstructured":"Centers for Disease Control and Prevention. Measles Cases and Outbreaks. 2014. Available from: http:\/\/www.cdc.gov\/measles\/cases-outbreaks.html [Accessed 3 September 2014]"},{"key":"e_1_3_2_156_1","unstructured":"The Lancet Infectious Diseases. A wake-up call for polio eradication 2014. Available from: http:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(13)70368-2\/fulltext%3Felsca1%3DETOC-TLID%26elsca2%3Demail%26elsca3%3DHTDJ [Accessed 4 September 2014]"},{"key":"e_1_3_2_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.060"},{"key":"e_1_3_2_158_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068038"},{"key":"e_1_3_2_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70191-3"},{"key":"e_1_3_2_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70584-9"},{"key":"e_1_3_2_161_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/430608","article-title":"Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine","volume":"41","author":"Long SS","year":"2005","unstructured":"Long SS. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005;41:30-4","journal-title":"Clin Infect Dis"},{"key":"e_1_3_2_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.09.026"},{"key":"e_1_3_2_163_1","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2014 global summary. 2014. Available from: http:\/\/apps.who.int\/immunization_monitoring\/globalsummary [Accessed 4 September 2014]"},{"key":"e_1_3_2_164_1","unstructured":"Johns Hopkins Bloomberg School of Public Health. VIMS Report: global Vaccine Introduction. 2013. Available from: http:\/\/www.jhsph.edu\/research\/centers-and-institutes\/ivac\/vims\/IVAC-VIMS-Report-2013-06.pdf [Accessed 9 August 2014]"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14712598.2015.993375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:15:44Z","timestamp":1770390944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14712598.2015.993375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,11]]},"references-count":162,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4,3]]}},"alternative-id":["10.1517\/14712598.2015.993375"],"URL":"https:\/\/doi.org\/10.1517\/14712598.2015.993375","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}